Patents Assigned to Rosetta Genomics Ltd
-
Publication number: 20190241966Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.Type: ApplicationFiled: December 19, 2018Publication date: August 8, 2019Applicant: Rosetta Genomics Ltd.Inventors: Ranit Aharonov, Nitzan Rosenfeld, Shai Rosenwald
-
Patent number: 10301627Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: November 15, 2017Date of Patent: May 28, 2019Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Publication number: 20190032142Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.Type: ApplicationFiled: March 1, 2018Publication date: January 31, 2019Applicant: Rosetta Genomics Ltd.Inventors: Ranit Aharonov, Nitzan Rosenfeld, Shai Rosenwald, Nir Dromi
-
Publication number: 20190010491Abstract: Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods ad compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.Type: ApplicationFiled: January 16, 2018Publication date: January 10, 2019Applicant: Rosetta Genomics Ltd.Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
-
Publication number: 20180127835Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.Type: ApplicationFiled: December 22, 2017Publication date: May 10, 2018Applicant: Rosetta Genomics Ltd.Inventors: Ranit Aharonov, Nitzan Rosenfeld, Shai Rosenwald
-
Publication number: 20180127755Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: November 15, 2017Publication date: May 10, 2018Applicants: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Patent number: 9845470Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: October 26, 2016Date of Patent: December 19, 2017Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Patent number: 9803247Abstract: The present invention provides a process for classification of specific cancers and tumors origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy.Type: GrantFiled: May 21, 2014Date of Patent: October 31, 2017Assignees: Rosetta Genomics, Ltd., Tel Hashomer Medical Infrastructure and Services Ltd.Inventors: Nitzan Rosenfeld, Shai Rosenwald, Iris Barshack, Dvora Nass
-
Patent number: 9765334Abstract: Described herein are compositions and methods for survival prediction in gastric cancer patients after surgical operation. The compositions are microRNA molecules associated with the prognosis of gastric cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.Type: GrantFiled: May 19, 2009Date of Patent: September 19, 2017Assignees: Rosetta Genomics, Ltd., Mor Research ApplicationsInventors: Moshe Hoshen, Raruch Brenner
-
Publication number: 20170137811Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: ApplicationFiled: October 26, 2016Publication date: May 18, 2017Applicants: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Patent number: 9650680Abstract: Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.Type: GrantFiled: July 13, 2016Date of Patent: May 16, 2017Assignee: Rosetta Genomics Ltd.Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
-
Patent number: 9650679Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.Type: GrantFiled: August 13, 2015Date of Patent: May 16, 2017Assignee: Rosetta Genomics Ltd.Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
-
Patent number: 9631236Abstract: The present invention is based in part on the discovery of a panel of miRs whose levels are increased or decreased in the circulation of chronic systolic HF patients. Accordingly, an extensive panel of miRs was screened in the sera of stable chronic systolic HF patients and the results were compared to an age, gender and ethnically matched control group.Type: GrantFiled: May 23, 2012Date of Patent: April 25, 2017Assignees: Rosetta Genomics Ltd., MOR Research Applications Ltd.Inventors: Yaron Goren, Ofer Amir
-
Patent number: 9624556Abstract: Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.Type: GrantFiled: July 13, 2015Date of Patent: April 18, 2017Assignee: Rosetta Genomics Ltd.Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
-
Patent number: 9540695Abstract: Described herein are compositions and methods for the prediction of the prognosis of ovarian cancer subjects. The present invention further provides methods for distinguishing between histological subtypes of ovarian cancer tumors, and also methods and compositions for the treatment or prevention of ovarian cancer. Specifically the invention relates to microRNA molecules associated with said methods and compositions, as well as various nucleic acid molecules relating thereto or derived therefrom.Type: GrantFiled: May 19, 2009Date of Patent: January 10, 2017Assignees: Rosetta Genomics Ltd., MOR Research ApplicationsInventors: Moshe Hosen, Gila Lithwick Yanai, Ram Eitan
-
Patent number: 9506062Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: August 24, 2015Date of Patent: November 29, 2016Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Patent number: 9487781Abstract: The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described.Type: GrantFiled: October 3, 2014Date of Patent: November 8, 2016Assignee: Rosetta Genomics Ltd.Inventor: Noga Yerushalmi
-
Patent number: 9340823Abstract: The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy.Type: GrantFiled: January 30, 2014Date of Patent: May 17, 2016Assignees: Rosetta Genomics, Ltd., Tel Hashomer Medical Research Infrastructure and Services Ltd.Inventors: Nitzan Rosenfeld, Yael Spector, Eddie Friedman, Zohar Dotan
-
Patent number: 9334540Abstract: The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids.Type: GrantFiled: October 25, 2013Date of Patent: May 10, 2016Assignees: Rosetta Genomics Ltd., MOR Research ApplicationsInventors: Yaron Goren, Shlomit Gilad, Moshe Hod, Yariv Yogev
-
Patent number: 9243296Abstract: Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.Type: GrantFiled: July 30, 2014Date of Patent: January 26, 2016Assignee: Rosetta Genomics Ltd.Inventors: Ayelet Chajut, Shai Rosenwald